Le Lézard
Classified in: Health
Subject: PLW

Mobius Therapeuticstm Granted New US Patent for Injected Ophthalmic Mitomycin-C


Critical New Intellectual Property Supports Regulatory Guidance, Compliance, and Clinical Technique

ST. LOUIS, Jan. 3, 2023 /PRNewswire/ -- Mobius Therapeuticstm, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, has been issued US Patent #11,540,977, Injection Apparatus and Method of Use.  This patent protects future applications of Mitosol®, Mobius' flagship product, particularly versus compounded, unapproved copies of Mitosol®.

"As the gold standard for ophthalmic mitomycin, this patent acknowledges the novelty and merits inherent to Mitosol®.  It protects the apparatus itself, its unique ability to protect healthcare workers, and its ultimate flexibility in accommodating all clinical needs."

"This is an important addition to Mobius' IP portfolio," said Ed Timm, CEO of Mobius Therapeutics.  "As the gold standard for ophthalmic mitomycin, this patent acknowledges the novelty and merits inherent to Mitosol®. It protects the apparatus itself, its unique ability to protect healthcare workers, and its ultimate flexibility in accommodating all clinical needs."

Mitosol® is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication.  With room temperature storage, shelf life of up to 24 months, and USP <800> compliance, Mitosol® offers unique flexibility to providers, as its "shelf-ready" status permits on demand utility.

"Ophthalmic surgeons are smart and resourceful physicians, relentlessly advancing clinical excellence with improved clinical technique," continued Timm.  "Mobiustm shares this passion; franchise protection provides the resources required to respond with products to meet and exceed these demanding needs, now and into the future.  In the end, everyone wins: the patient, the provider, and the American healthcare system."

About Mobius Therapeutics, LLC:

Mobius Therapeutics is a commercial stage venture focused on sterile perioperative ophthalmic pharmaceuticals.  Mitosol® (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use, is the only formulation of mitomycin-c bearing an ophthalmic indication.  Mobius maintains additional perioperative formulations in commercialization, as well as an active product pipeline.  Please see full prescribing information at https://mitosol.com/mitosol-package-insert/.

CONTACT:
Ed Timm
Mobius Therapeutics, LLC
314-615-6932
[email protected]

SOURCE Mobius Therapeutics, LLC


These press releases may also interest you

at 07:50
Shoppers Drug Mart partners with Avicanna to transition Medical Cannabis by Shoppers 
Avicanna Inc. ("Avicanna" or the "Company) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that Shoppers Drug Mart® ("Shoppers") has...

at 07:50
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered...

at 07:35
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel...

at 07:30
Digital Diagnostics Sheds Light on AI Tech with LumineticsCoretm Product Rebrand
Digital Diagnostics ? a leading AI diagnostics company on a mission to transform global healthcare ? has rebranded its flagship product, the AI diagnostic system formerly known as IDx-DR, to LumineticsCoretm....

at 07:30
PATHWAY ANNOUNCES FINAL DRAW-DOWN UNDER BRIDGE LOAN
Pathway Health Corp. ("Pathway" or the "Company") is pleased to announce that, further to its press releases of February 3, 2023, February 9, 2023 and February 17, 2023, it has made its third and final draw in the amount of $250,000 (the "Draw...

at 07:25
MIT Sloan School of Management researchers help redesign national lung transplant allocation system using data analytics
United Network for Organ Sharing (UNOS) has rolled out a new organ allocation system designed to be more equitable and effective for patients in need of lung transplants....

More news about Health...


News published on 3 january 2023 at 10:00 and distributed by: